GLAdiator Biosciences

Developing a novel drug-targeting platform which focuses on the ability of naturally occurring gamma-carboxyglutamic-acid (GLA) domains to identify and detect Phosphatidylserine (PS), which is uniquely expressed on the surface of cancer cells vs healthy cells. This technology has potential to deliver selective drug-targeting that is independent of the receptor, endosomal and lysosomal pathway, and circumvent other complexities of Ab-based approaches.